How should companies budget for PCT national-phase entry in 2026?

The direct answer to budgeting for PCT national-phase entry

A PCT national-phase budget should be built as a portfolio of country-specific decisions rather than as one global filing fee. The basic international PCT phase is already paid before national-phase entry, so the next budget must cover each elected office’s national fees, translations, representation, local claims, publication or examination requests, and later renewal fees. As a planning baseline, a company should identify its likely market by about 12 months after the earliest priority date, make a preliminary national-phase selection by month 18, and commit to final filing instructions by the applicable month 30 or month 31 deadline. Many applicants also allocate three months beyond the entry deadline for correction of formal defects. Exact amounts depend heavily on the number of countries, claim count, translation volume, procedural status, and whether the applicant starts from an international application or enters directly from a prior national application. A defensible budget therefore distinguishes unavoidable filing charges from optional prosecution services and reserves rather than advertising an unsupported all-inclusive total.

Also worth reading: How Do PCT National Phase Fees Affect Patent Costs and Deadlines in 2026? · What Is an IP Registry Implementation, and How Should Companies Choose One? · How Should Companies Conduct Indian Trademark Clearance Before Filing an Application?

For a simple internal model, a smaller three-country program may be estimated in the low five figures of US dollars, while a larger multi-country portfolio can reach tens of thousands. Those ranges are planning estimates, not official quotations. Official fees generally include a basic national fee, but a single total often fails to capture translation expense, local attorney fees, excess-claim charges, priority examination, and annuity costs. A company with substantial commercial value in several jurisdictions should budget separately for entry, the first two or three years of prosecution, and maintenance after allowance. The PCT coordinate designation itself, and any state in which the applicant has no interest, should not be included merely because it appeared in an early search or discussion.

How the PCT national-phase timetable controls cash flow

The PCT does not itself produce one global patent: international publication under the PCT normally begins national-phase procedures in each elected state. Under PCT Article 22, the applicant generally has 20 months from the priority date to furnish a demand for international preliminary examination in the form required by each designated Office, while Article 39 allows applicable Offices to require 30 months for national-phase entry. PCT Article 24 allows applicable Offices to allow 31 months when the international application was filed in electronic format. This is why budget teams must identify the exact receiving Office and filing method rather than assume a universal 30-month date. In India, for example, applicants must check the current Indian Patent Office form, fee schedule, and permitted filing method instead of relying on a secondary article or a stale international calendar.

A useful cash-flow plan therefore has three gates. At month 12, confirm the PCT filing, priority claim, invention disclosure, and provisional filing; at month 18, rank jurisdictions using expected revenue, competitors, freedom-to-operate exposure, manufacturing, and enforcement value; and by month 26, obtain country-level estimates and reserve funds. Instructions for multiple designated states need not always be submitted together, but allowing every office to the last possible day creates procedural and translation risk. If the earliest priority date is 1 January 2026, the likely entry window is January 2026 through January 2027 for a normal national route, with the precise deadline determined by the competent Office. The PCT Applicant’s Guide and each Office’s official fee and form pages should control the operative dates.

What costs must be included in the national-phase budget

The first cost category comprises official filing and examination charges payable to each national or regional office. These can include a basic national-phase fee, a handling or procedural fee, a translation fee, and surcharges for excess claims or pages. Some offices also assess a fee when confirming the invention’s priority or when applicants choose a particular examination request. The PCT international-phase fee, search fees, and international publication fee should not be charged a second time merely because the application later enters national phases. Fees paid in the international phase also should not be confused with national annuities, which begin or become payable according to the receiving office’s rules and may include third-year or later renewal charges.

The second category is professional work by patent attorneys or agents. National-phase filing is not simply the mechanical forwarding of documents: counsel adapts the specification, verifies whether amendments are needed, pays local fees, manages translation instructions, and monitors formalities. If no international search report, written opinion, or international preliminary examination report is available, the national route may involve supplemental searching or examination structures that affect the strategy and cost. Translation is a separate variable. A claim set of 20 claims translated into Japanese, for example, is economically different from an untranslated European filing, and machine translation is not a substitute for a filing accepted in the relevant language unless the Office expressly permits it.

The third category is the continuing prosecution budget. A national-phase estimate that stops at entry is incomplete because substantive action may include responding to office actions, attending hearings, claiming priority, and securing allowance. For a three-country program, counsel might prepare a first-year reserve and a separate allowance and grant reserve. It is sensible to budget renewal fees for the expected term, but not every country should automatically be funded through the same year: some commercial programs can be reduced after an office action, some jurisdictions have low enforcement value, and others become more important after competitors or regulatory changes emerge. An international portfolio dashboard should display entry cost, forecast prosecution cost, next payment date, owner, business sponsor, and abandonment threshold.

Direct national filing versus continued PCT prosecution

Before the first PCT payment, the applicant should compare direct national filing with a PCT application and, if a PCT application is used, compare filing in one receiving Office with pursuing a second national application. Direct filing can avoid some PCT coordination and international-phase expenses, particularly where the target country is clear, the invention is simple, and translation or local representation costs are modest. It is often inefficient for a product likely to be sold in five or more important markets, because separate priority filings consume more drafting, administrative effort, and duplicated work. The PCT is most useful when international search, deferred national decisions, and a common disclosure package justify those early costs.

The continuation route matters because the PCT application can be filed nationally at month 12, while national-phase entry typically arrives around months 30 or 31. A 20-month filing can sometimes help an applicant make a more informed selection, but the international application will not have benefited from a later commercial update unless the disclosure remains sufficiently supported. A continuation is not a mechanism for adding unrelated subject matter merely to preserve every possible option. Budget reviewers should compare the incremental value of each period with the risk that claims may need to be narrowed, that costs accrue while decisions are deferred, and that the applicant has not obtained an early national search result.

## A practical budgeting process from disclosure to instruction

Start with a written business ranking rather than with an office-fee spreadsheet. Assign each target country a 1–5 score for expected sales, manufacturing, customer contracts, regulatory clearance, competitive activity, freedom-to-operate importance, and enforceability. A country scoring 1 does not automatically merit filing; a country scoring 5 should explain why the application is being abandoned. Then inspect the family and confirm the earliest priority date, because that date drives the national-phase deadline. Check whether the application includes sequence listings, drawings, software, biotechnology, or unusually extensive claims, all of which can influence translation, formalities, and search costs.

Next, prepare a country card containing the competent office, language, local representative need, entry deadline, official forms, basic fee, translation requirement, annuity schedule, estimated attorney fee, and expected examination route. A central counsel team can own the commercial decision while local counsel validates the procedural details. The PCT Applicant’s Guide and official receiving-office pages should be treated as the operational references; an article describing a related PCT or national procedure is not enough. The budget should be approved in stages, with an initial filing reserve, a national-entry reserve, and a later prosecution reserve. This staged approach prevents a company from paying for every country on the designation page when its actual commercial plan has changed.

A common planning formula is: multiply the expected number of national filings by the average official entry cost, then add translation costs, local counsel fees, an allowance reserve, and a contingency of roughly 10% to 20% for exchange rates, page or claim surcharges, and missed procedural assumptions. The contingency is a management provision, not a government fee. Currency conversion matters because international firms may invoice in dollars, euros, pounds, yen, or local currency. The same formula should be rerun after publication, the international search report, or an international preliminary examination report, because those documents can alter country priority and the number of claims worth pursuing.

Common mistakes that make PCT national-phase budgets unreliable

The most frequent error is treating “PCT national phase” as a single transaction. There is one international application, but there are multiple national-phase acts, each with its own office, language, fee, deadline, and prosecution system. Another error is assuming that every country must be entered by the same day. PCT Article 22 and Article 39 provide a framework for 20-, 30-, and, where permitted, 31-month routes, but the exact national rule and filing method control. Applicants should also avoid using a third-party estimate as a quotation; official fees change, and professional charges vary by scope.

A second common mistake is budgeting for filing but not for translations. Translation volume is determined by the documents that must be localized, and some offices require more than a literal translation of the claims. A third is assuming that an international search report is equivalent to a national grant. It can reduce uncertainty, but it does not bind a national office. A fourth is failing to account for the possibility of unity-of-invention objections, amended claims, multiple priorities, or a restriction of the invention’s commercial scope. Finally, many budgets omit abandonment costs and the labor needed to reconcile national-phase instructions with the business plan. A clear “go,” “review,” or “stop” rule for each market is more useful than an unexplained list of all PCT designated states.

How alternatives affect cost and timing

National, regional, and validation routes should be compared as alternatives rather than treated as equivalent labels. The European patent route can cover participating European states through a single procedure, but the route has its own fees, translation arrangements, and the question of later validation in individual states. Regional applications elsewhere may have different member states, renewal systems, and enforcement structures. A direct Paris Convention filing can be appropriate where a single country matters, while a PCT application is usually more administratively efficient for a genuinely international filing program. None of these routes guarantees a patent in every desired country.

Divisional applications, continuation applications, and national-phase amendments are additional options, not free extensions of the original budget. A divisional filing may be useful where different technical contributions or business markets justify separate portfolios, but it creates another disclosure, priority, fee, and deadline analysis. A national-phase request for examination or a specialized examination track may reduce time in some offices but can increase the immediate fee. Applicants should ask whether the commercial benefit justifies the acceleration. A professional cost comparison should therefore show not only the fee today, but also the expected cost of maintaining, enforcing, validating, or abandoning the resulting right.

For budgeting purposes, the applicant should obtain at least one current quote for a representative country in each major fee, language, and filing structure. The quote should say whether it includes priority claim, amendments, translation, local representation, official fee, disbursements, and prosecution through allowance. A low entry quotation that excludes prosecution is not comparable with a full-service estimate. Conversely, a high quote that includes five years of annuities and grant fees should not be presented as a filing-only comparison. This discipline makes the budget more useful to finance teams and more honest to the patent committee.

When to act and what decision triggers should be used

The applicant should not wait until month 30 to determine whether a country is important. At 12 months after priority, confirm that the PCT application is commercially and technically coherent; at 18 months, prepare a preliminary national list; and no later than 24 months, obtain preliminary cost estimates. A 26–27-month internal lock date gives representatives time to confirm forms and translations before the applicable 30- or 31-month deadline. If the PCT has not yet been filed, the decision to use the PCT should be made before making separate national filings that might create avoidable duplication or inconsistent disclosure.

The decision to enter a country should be revisited when new evidence appears: a signed distribution agreement, a regulator’s requirement, a competitor’s launch, a manufacturing move, or a freedom-to-operate concern. Conversely, a product cancellation, a failed market screen, or a narrow claim set can justify omitting a country. This is not an automatic abandonment, because rights and business priorities may change again. It does mean the budget should be refreshed after the international search report and before final instructions, and again when a national office indicates substantive issues.

For a portfolio team, the practical trigger is simpler: every national filing should have an owner, a business reason, a next decision date, and an estimated cost through the next meaningful milestone. If no one can explain why the country matters or who will fund prosecution, the filing is a candidate for review. That review is especially important for applicants using a PCT precisely because it makes additional countries administratively possible. Flexibility has value only when the applicant has the discipline to use it. A smaller, well-funded program in the countries that support revenue and enforceability is generally preferable to a large list of uncertain rights.

A sensible 2026 budgeting example

Suppose a medical-device company has a 20-claim PCT application, three priority countries, and a possible fourth market. It might first estimate entry fees for the three priority countries, then add certified or professionally reviewed translations for each required language. Local counsel budgets should be quoted separately for filing and for examination, while the company reserves an amount for office actions, amendments, and grant-stage fees. A fourth country is included only if the new market is supported by a contract, regulatory pathway, or a documented competitive need; otherwise its cost remains an option rather than a committed expense.

The same example shows why a single PCT number is misleading. A five-country portfolio with short claims and common languages may cost less than a two-country portfolio requiring extensive technical translation and local representation. A company should not decide that the PCT is “expensive” merely because it has more countries, nor assume that the cheapest route is the most useful. It should compare the expected commercial life of the product, the cost of delay, the probability of meaningful claims being allowed, and the cost of monitoring third parties. At month 27, the company can retain the strongest markets, defer a borderline country to the next available national route if the office permits it, and cancel prosecution where the expected value no longer justifies spending.

The final budget is a living control. Official fees should be checked close to filing, exchange rates and counsel estimates should be refreshed, and the dashboard should record what each payment purchased. The most authoritative result is not the largest national portfolio; it is a documented set of decisions showing why each country was selected, how its deadline was met, and what commercial outcome the applicant expected. For B2B IP and registry teams, that record also supports auditability, client reporting, and consistent handling of later renewals or portfolio changes. The PCT should be used as a disciplined strategic and financial tool, not as a reason to postpone all resource allocation decisions until the national-phase threshold arrives.